High-grade dysplasia in Barrett's oesophagus: natural history and review of clinical practice

Aliment Pharmacol Ther. 2005 Mar 15;21(6):747-55. doi: 10.1111/j.1365-2036.2005.02401.x.

Abstract

Background: Management of high-grade dysplasia in Barrett's oesophagus is controversial: surgery carries an appreciable morbidity/mortality, high-grade dysplasia may not progress to cancer and endoscopic ablation is an emerging option.

Aim: To review Barrett's oesophagus-related high-grade dysplasia management and outcome over a 10-year period.

Methods: This was a retrospective case note review of 36 patients identified from a pathology database.

Results: There were 31 men of mean age 67 years. Endoscopic surveillance identified nine. Median follow-up was 21 months. Seven patients had no further intervention because of age/comorbidity. The other 29 had repeat endoscopic biopsies, nine showing cancer (six oesophagectomized). Of the 20 remaining patients with persisting high-grade dysplasia, eight had surgery (histology showed cancer in six), seven continued endoscopic surveillance (high-grade dysplasia regressed in four) and five had 'curative' argon ablation. An intensive biopsy protocol was not followed in 55% of endoscopies. Prevalent cancers occurred in 44% with an annual incidence of 5% over 5 years. All cause mortality was 39% (14 of 36, eight of 14 from cancer).

Conclusions: Management of high-grade dysplasia was not uniform. Unsuspected cancer was common in high-grade dysplasia patients undergoing surgery but 13% regressed under surveillance. High-grade dysplasia patients have a high mortality but 43% did not die from cancer.

Publication types

  • Multicenter Study

MeSH terms

  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Adult
  • Aged
  • Aged, 80 and over
  • Barrett Esophagus / pathology
  • Barrett Esophagus / therapy*
  • Biopsy
  • Esophageal Neoplasms / pathology
  • Esophageal Neoplasms / therapy*
  • Esophagectomy / methods
  • Esophagus / pathology*
  • Female
  • Humans
  • Laser Coagulation / methods
  • Male
  • Middle Aged
  • Neoplasm Staging / methods
  • Precancerous Conditions / pathology
  • Precancerous Conditions / therapy*
  • Proton Pump Inhibitors
  • Retrospective Studies
  • Survival Analysis
  • Treatment Outcome

Substances

  • Proton Pump Inhibitors